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methods in clinical research settings 
Abstract 
Introduction: Data audits within clinical settings are extensively used as a major strategy to identify errors, 
monitor study operations and ensure high-quality data. However, clinical trial guidelines are non-specific 
in regards to recommended frequency, timing and nature of data audits. The absence of a well-defined 
data quality definition and method to measure error undermines the reliability of data quality assessment. 
This review aimed to assess the variability of source data verification (SDV) auditing methods to monitor 
data quality in a clinical research setting. 
Material and methods: The scientific databases MEDLINE, Scopus and Science Direct were searched for 
English language publications, with no date limits applied. Studies were considered if they included data 
from a clinical trial or clinical research setting and measured and/or reported data quality using a SDV 
auditing method. 
Results: In total 15 publications were included. The nature and extent of SDV audit methods in the articles 
varied widely, depending upon the complexity of the source document, type of study, variables measured 
(primary or secondary), data audit proportion (3-100%) and collection frequency (6-24 months). Methods 
for coding, classifying and calculating error were also inconsistent. Transcription errors and 
inexperienced personnel were the main source of reported error. Repeated SDV audits using the same 
dataset demonstrated ∼ 40% improvement in data accuracy and completeness over time. No description 
was given in regards to what determines poor data quality in clinical trials. 
Conclusions: A wide range of SDV auditing methods are reported in the published literature though no 
uniform SDV auditing method could be determined for "best practice" in clinical trials. Published audit 
methodology articles are warranted for the development of a standardised SDV auditing method to 
monitor data quality in clinical research settings. 
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Introduction: Data audits within clinical settings are extensively used as a major 39 
strategy to identify errors, monitor study operations and ensure high-quality data. 40 
However, clinical trial guidelines are non-specific in regards to recommended 41 
frequency, timing and nature of data audits. The absence of a well-defined data 42 
quality definition and method to measure error undermines the reliability of data 43 
quality assessment. This review aimed to assess the variability of source data 44 
verification (SDV) auditing methods to monitor data quality in a clinical research 45 
setting. Material and methods: The scientific databases MEDLINE, Scopus and 46 
Science Direct were searched for English language publications, with no date limits 47 
applied. Studies were considered if they included data from a clinical trial or clinical 48 
research setting and measured and/or reported data quality using a SDV auditing 49 
method. Results: In total 15 publications were included. The nature and extent of 50 
SDV audit methods in the articles varied widely, depending upon the complexity of 51 
the source document, type of study, variables measured (primary or secondary), 52 
data audit proportion (3-100%) and collection frequency (6-24 months). Methods for 53 
coding, classifying and calculating error were also inconsistent. Transcription errors 54 
and inexperienced personnel were the main source of reported error. Repeated SDV 55 
audits using the same dataset demonstrated ~40% improvement in data accuracy 56 
and completeness over time. No description was given in regards to what 57 
determines poor data quality in clinical trials.  Conclusions: A wide range of SDV 58 
auditing methods are reported in the published literature though no uniform SDV 59 
auditing method could be determined for “best practice” in clinical trials. Published 60 
audit methodology articles are warranted for the development of a standardised SDV 61 
auditing method to monitor data quality in clinical research settings.  62 
 63 
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1. Introduction 67 
Clinical trials are vital to enabling a greater understanding of how interventions work 68 
in humans [1]. Therefore, it is essential that clinical trials produce accurate, complete 69 
and relevant data [2, 3]. The integral nature of good quality data and documentation 70 
practice is well accepted within the research community as conclusions and 71 
recommendations rely heavily on the outcomes of the data. As part of quality 72 
assurance practices, modifications to study practices are made to prevent errors 73 
occurring, however, no universally accepted method for measuring error rates 74 
currently exists [4]. Within the published literature, it is generally accepted that if 75 
greater than 10% of data is missing or incorrect, analysis of the data is considered to 76 
be unreliable [5, 6]. Data audits are conducted to verify that data is appropriately 77 
documented, coded and classified and may assess compliance to a protocol. To 78 
allow for this all data must be recorded on source documentation to reconstruct the 79 
trial as it happened and allow for an independent observer to confirm the data 80 
validity [7]. Without source data, audits cannot be completed and the fundamental 81 
principle of protecting participant rights, safety and well-being cannot be guaranteed. 82 
Therefore, data audits work closely with quality assurance processes by allowing on-83 
site monitoring activities to aid study investigators to improve data quality and overall 84 
study operations. Quality assurance audits, within clinical settings, are extensively 85 
used and are a significant strategy to ensure high-quality data [4, 5, 8, 9]. However, 86 
on-site audits are infrequently published or reported. This may be due to non-specific 87 
audit methods, lack of time and funding or the publishing of audit methodology is not 88 
seen as a ‘value added’ activity [10-12]. Published methodology papers are 89 
warranted to promote routine auditing within academic and commercial clinical 90 
research settings.  91 
 92 
In clinical trials auditors should evaluate whether the data is collected and managed 93 
in accordance with a known quality standard such as the International Conference 94 
on Harmonisation (ICH) guideline E6 on Good Clinical Practice (GCP), 1996 [13]. 95 
According to the ICH-GCP, there is a need for on-site monitoring before, during and 96 
after a clinical trial, but they do not specify the frequency and nature of such 97 
monitoring. This refers to the complete clinical record of the participant and includes 98 
the process of applying eligibility criteria and participant consent throughout the trial 99 
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until the participant completes the study and the report is published [7]. The practice 100 
of source data verification (SDV) fulfills the ICH-GCP requirements and is a process 101 
of comparing data collected on original source documents to data recorded on a 102 
case report form (CRF) or electronic record [13]. Source documents are considered 103 
the “gold standard” from which data is obtained in clinical trials [10, 14, 15]. The 104 
United States Food and Drug Administration (FDA) released a guideline in 1988 for 105 
Monitoring of Clinical Investigations leading to a general agreement that completing 106 
100% SDV was required to meet the needs for high data quality and integrity [16]. 107 
These guidelines have since been withdrawn. The updated guidelines [17] promote 108 
the use of alternative monitoring methods such as, risk-based approaches to 109 
monitoring. Similarly, an updated ICH guideline E6(R2) was released in 2015 which 110 
addressed audits, though the guideline still does not provide detail regarding auditing 111 
methods and an ‘acceptable’ level of error [18]. The guidelines suggest that “when 112 
significant noncompliance is discovered, the sponsor… should perform a root cause 113 
analysis and implement appropriate corrective and preventative actions. If required 114 
by applicable law or regulation the sponsor should inform the regulatory 115 
authority(ies) when the noncompliance is a serious breach of the trial protocol or 116 
GCP”[18]. Without a clear definition of what ‘noncompliance’ and ‘serious’ breach 117 
refer to, it is left up to interpretation of the investigator. This leaves individual 118 
organisations to set their own approach for data auditing, thus justifying the need for 119 
clear and suitable systematic methods to monitor data quality. 120 
 121 
The cost-effectiveness of SDV has been questioned; it is an expensive and labour 122 
intensive activity [10] with estimates that monitoring site data represented 25-30% of 123 
the total study cost [19]. Research grants seldom include funding for an audit 124 
program [20], however, costs may be reduced by 40% by simultaneously reducing 125 
the amount of data collected and number of on-site visits. Further, as quality 126 
assurance improves and is reinforced throughout a study, the cost of completing 127 
audits, in turn, decreases [10]. Nevertheless, it is recognised that effective annual 128 
data audits on 10-20% of records are a cheaper solution [10] though the suggestion 129 
of a 5-10% random sample of participant records has been considered adequate for 130 
on-site auditing [21]. It is often assumed that a greater percentage of data audited is 131 
associated with improved data quality; although there is no experimental or statistical 132 




Thus, the aim of this review is to assess the variability of SDV auditing methods to 135 
monitor data quality in a clinical research setting. It was hypothesised that data 136 
quality variations are due to unclear SDV auditing methods existing within clinical 137 
research settings. 138 
 139 
 140 
2. Material and methods 141 
A literature review was conducted with reference to frameworks for establishing 142 
evidence for practice provided by the Australian Government National Health and 143 
Medical Research Council (NHMRC) [23] and followed the requirements of the  144 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 145 
checklist [24]. To ensure a standard and detailed method was applied the Cochrane 146 
Handbook for Systematic Reviews of Interventions was consulted for guidance [25]. 147 
Studies reviewed were assessed for quality to identify potential risk of bias using the 148 
Academy of Nutrition and Dietetics Evidence Analysis Library quality rating checklist 149 
[26]. The review addressed the research question, “Is there consistency in SDV 150 
auditing methods to monitor da ta quality in clinical research?”  151 
 152 
A methodical search was conducted using MEDLINE, Scopus and Science Direct 153 
scientific databases to identify relevant articles that had assessed data quality 154 
through the use of a SDV audit. An identical search strategy was applied using the 155 
following keywords: (source data verification OR source document verification OR 156 
data monitor* OR data collect*) AND (quality control OR quality assurance) AND 157 
(medical trial OR medical record OR clinical trial OR clinical record) AND (medical 158 
audit OR clinical audit OR data audit OR audit) AND (data quality OR data integrity 159 
OR data quality improvement) AND (error* OR data). No date limits were set for the 160 
search.  Publications were restricted to those published in the English language due 161 
to lack of translation resources and included only human participants. This ad-hoc 162 
literature review was undertaken to focus on clinical research trials who have 163 
implemented SDV auditing methods. Medical Subject Heading (MeSH) were 164 
deemed inappropriate due to the topic of research being an emerging area within the 165 
literature. Specific MeSH terms are used to describe articles for medical records 166 
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while this research focuses on clinical research. Potentially relevant articles were 167 
screened by title and abstract and subsequently through full-text if required. Where 168 
data was not immediately available in the published article, reference lists were 169 
hand-searched and corresponding authors were contacted to clarify outcomes.  170 
 171 
 172 
3. Results  173 
A total of 802 articles were identified with 183 articles not meeting the inclusion 174 
criteria (49=non-English and 134=non-human participants). Please refer to Figure 1 175 
for full details. 176 
 177 
3.1 Description of studies 178 
Ultimately, 15 relevant published articles were scrutinised and summarised in Table 179 
1. Eight articles assessed the accuracy, completeness, and reliability of a database 180 
[14, 15, 27-32] and seven assessed the performance and value of a SDV method [5, 181 
6, 9, 12, 33-35]. There was substantial heterogeneity in study design, in particular 182 
with respect to error coding, classification, and calculation. Three articles reported 183 
data from randomised controlled trials (RCTs) [27, 28, 33]; three from comparative 184 
cohort studies [9, 15, 29]; two from interrupted time series with no control [12, 14]; 185 
two from historical control studies [5, 6]; three from cohort studies with no 186 
comparison [30, 31, 34]; one from a single-arm study [35] and one from a pre-187 
test/post-test study design [32]. All 15 articles were deemed to have sound study 188 
design and scientific rigour overall (Additional file 1). 189 
 190 
 191 
The types of clinical studies from the 15 included articles are summarised in Table 2. 192 
Although no year restriction was applied, the majority of publications were published 193 
within the past ten years (n=10) and represent studies in six different countries within 194 
institutional (n=10) and academic research (n=5) organisations. Studies 195 
implemented various auditing methods to suit individual policy and procedures for 196 
study design. 197 
 198 
3.2 Methods of source data verification 199 
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The nature and extent of the SDV audit methods varied depending upon the amount 200 
of data collected and the complexity of the source document [5]. Data 201 
inconsistencies resulted from how studies recorded information and how they 202 
entered, stored and formatted the data [29]. Two articles demonstrated that health 203 
records and auditing tools differed within the same study [9, 29]. Good data quality 204 
also appeared to be related to the effectiveness of data-monitoring plans which had 205 
a functioning structure and efficiently organised data [34]. In turn, knowledge, and 206 
experience of data entry personnel involved in data management were related to the 207 
error rate [34]. Abstraction and transcription of data were identified as the steps most 208 
likely to introduce error [5, 34]. Similarly, the design of the CRF was considered 209 
important to minimise error and needs to be emphasised [34].  210 
 211 
Three publications which implemented multiple SDV audits on the same dataset 212 
found an improvement in data quality over the duration of the study [12, 15, 29]. 213 
Completion of a re-audit reported a 50% decrease in the overall error rate. The 214 
remaining errors existed due to data existing on the source document but not 215 
entered into the database, rather than minor and major incorrect values [29]. 216 
Mphatswe et al. [12] found the level of completeness increased 38% and accuracy 217 
increased 28% when comparing the first and third audits. A re-audit of data elements 218 
was identified as suboptimal and should only be targeted for further continuous data 219 
quality interventions [15, 32]. 220 
 221 
SDV was considered to be time-consuming, expensive and not necessarily free from 222 
error [9, 28, 33, 35], however, interpretation of on-site issues provided much more 223 
than just identification of error [6]. For example, identifying whether errors were 224 
systematic allowed for potential solutions and recommendations to be introduced for 225 
overall quality improvement [5, 6]. Two publications suggested that central 226 
monitoring, such as remote SDV and risk assessment are more effective at 227 
identifying data errors when compared to traditional on-site 100% SDV, the method 228 
recommended by the ICH-GCP [9, 33]. For a precise understanding of how and 229 
where errors lie within a dataset,  on-site monitoring can provide greater insight into 230 
problems and aid in identifying potential solutions for improvement, not only within 231 




3.3 Variables, frequency, and amount of source data verification  234 
Only one included publication completed traditional on-site 100% SDV [34]. All 235 
others completed a random sample of data points, CRFs, study participants or 236 
centres. Key data variables were not defined consistently but included important data 237 
items such as primary and secondary endpoints, informed consent, eligibility criteria, 238 
randomisation distribution, adverse events and safety data [5, 9, 12, 14, 27, 28, 33]. 239 
Further to this, seven publications did not state or specify if variables were critical to 240 
the outcome of the study [6, 15, 29-32, 35].  241 
 242 
The frequency of SDV audits was stated in nine publications, in which two conducted 243 
SDV before, during and after data entry [12, 28], though one did not report on 244 
specific time intervals [12]. Time points varied (6-24 months) between publications 245 
[9, 15, 28, 31, 35] and this was due to study design and/or implementation of study 246 
interventions such as an electronic medical record (EMR) [14].  Two publications 247 
depended on completing a second audit based on the percentage of expected 248 
participant enrollments (20-30% and 70-80%) [5] as well as identifying sites that 249 
required major quality interventions [29]. However, no description was given in 250 
regards to what determined poor quality data.  251 
 252 
The number of participants, files and centres included for each SDV audit varied and 253 
the amount of SDV varied depending on the nature and size of the data generated. 254 
Random sampling was the most common auditing method implemented, however 255 
the amount of participants (8-94%) [9, 14, 15, 27-30, 33], files (3-10%) [31, 35] or 256 
centres (11-35%) [6, 12, 32] randomly selected differed substantially. The remaining 257 
two publications implemented methods including; a specific number of files per 258 
centre, [34] and expected participant enrolment [5]. 259 
 260 
3.4 Error coding, classification, and calculation  261 
The method used to code, classify and calculate error varied widely. Of the 14 262 
publications that classified or coded data only eight provided clear definitions for the 263 
codes [5, 9, 12, 27, 29, 31, 34, 35]. One did not specify coding or an explanation of 264 
how error rates were calculated at all [28]. Published auditing methods were 265 
implemented in four publications, the National Cancer Institute (NCI) method for 266 
auditing cases [5, 27] and the European Organisation for the Research and 267 
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Treatment of Cancer (EORTC) [29, 34]. The total error was described in the 268 
literature by dividing total erroneous and missing points by total audited points [5, 14, 269 
29], a standard error calculation [30, 31], and calculating an agreement rate [6, 12]. 270 
Thus, dissimilarities in the available auditing methods were a key finding 271 
demonstrating the heterogeneity in SDV auditing methods. 272 
Identifying errors through retrospective checking and data cleaning was a more 273 
successful method when compared to detection through data entry itself [28]. 274 
Reporting of error rates depended on how data was abstracted within the individual 275 
studies and results varied greatly (<1% to 71%). No systematic pattern was 276 
determined for CRF-to-database audits. Reported discrepancies had a minor impact 277 
on the primary outcome of the study, with the error reported at <1% [5, 33]. On the 278 
other hand, both source document-to-database and source document-to-CRF 279 
average error rates were much greater (~10-20%) for the majority of publications 280 
(n=9). The main source of error (0.4-14.5%) was from transcribing data from paper to 281 
electronic records [34]. Knowledge and experience of the data management and 282 
entry personnel were directly related to efficient data collection and organisation, 283 
which was linked to the percentage of error found [34].  284 
 285 
Visual inspection, by manually checking data through SDV, allows identification of 286 
errors that fall outside predetermined values [28, 32]. The majority of publications 287 
implemented continuous extensive range, logic, and consistency checks via an 288 
electronic database [5, 6, 28, 30, 32, 33]. Errors within these articles were 289 
considerably lower when compared to those that did not implement additional 290 




4. Discussion 295 
This literature review has identified that there are limited methodological publications 296 
available on quality assurance procedures within clinical research settings. With the 297 
available published data, this review highlights the heterogeneity of SDV auditing 298 
practices and the significant variations in procedures, policies, requirements, and 299 
technologies of the audit designs used in clinical studies. As only four publications 300 
used an established SDV audit method considerable variation amongst terminology 301 
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and methodology was found [5, 27, 29, 34]. Parallel with results from this literature 302 
review a survey conducted by the Society of Clinical Data Management reported up 303 
to seven different methods used to calculate error rates leading to variances in the 304 
results [4]. Therefore, it is evident there is a need to create clear definitions and 305 
guidelines to avoid ambiguity.  306 
 307 
This literature review identified that completing 100% SDV requires careful 308 
consideration as it does not guarantee error-free results. Interestingly, only one 309 
publication in this review completed traditional 100% SDV of all data points [34]. 310 
Additionally, key data for auditing was defined inconsistently throughout studies and 311 
variations may have been subject to the study investigators personal judgement. 312 
However, completing 100% SDV on secondary data that is not subsequently used 313 
for analyses may not be cost-effective. This aligns with Eisenstein et al. [19] who 314 
compared the amount of data collected and the effect this had on the cost of the 315 
clinical trial. They found that the most efficient way to reduce trial costs, without 316 
compromising scientific objectives, was to reduce the number of on-site monitoring 317 
visits. Despite this, the Institute of Medicine is concerned that any discrepant data 318 
points identified during monitoring will bring into question the reliability and validity of 319 
the whole dataset [36]. From the outcomes of this review the authors suggest that 320 
data audit characteristics such as conducting 100% SDV on critical endpoints and 321 
random selection of 10% SDV of non-critical endpoints, could be a more accurate 322 
and cost-effective method to ensure data quality. A quality improvement plan should 323 
be implemented for a follow-up audit if the error is found to be greater than 10%, to 324 
revise and improve site procedures. This suggested data audit method would need 325 
to be tested against a traditional method (e.g. 100% SDV) to provide evidence for 326 
implementation. 327 
 328 
Although there is currently a lack of knowledge regarding alternative auditing 329 
methods, the literature supports changing the focus from on-site SDV audits to 330 
employing other methods to monitor clinical trials [33]. Central monitoring techniques 331 
such as risk-based monitoring, which include identifying critical errors by a risk-332 
algorithm or risk-assessment model, have been recently welcomed by the research 333 
community. Critical errors are those that are crucial to the quality of the data and 334 
may affect the primary outcome of the study. Thus, quality assurance is determined 335 
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based on the level of risk identified and assessed on various critical data points or 336 
activities. Two large academic groups in France [37] and Germany [38] are 337 
conducting large RCTs comparing risk-based monitoring and on-site SDV and 338 
compliance with GCP. The German group recently (August 2017) published findings 339 
that risk-based monitoring utilises less than 50% of resources compared to intensive 340 
on-site monitoring, which only had a small benefit (8.2%) relative to the overall 341 
findings [39]. This study is a major step towards improving auditing methods. 342 
Previously in the literature, other researchers have captured and overlapped 343 
essential elements of established sociotechnical models to evaluate the acceptance 344 
of new technology into a unified theoretical model [40]. The researchers’ suggest, 345 
based on the analysis of the current literature, that future research should draw on a 346 
similar approach and include the strongest elements of previously tested methods 347 
and investigate the feasibility of creating a single consolidated method for all clinical 348 
research. However, it is essential that the method allow for adaptations according to 349 
study context and data availability. 350 
 351 
With emerging literature on technology improvements, there are new opportunities 352 
and concerns about the increase in reuse of clinical research data. The American 353 
Medical Informatics Association stressed the urgency and complexity of issues that 354 
surround the secondary use of clinical data and compiled a set of recommendations 355 
that warrant the need for standards and clear rules to define evidence [41]. 356 
Additionally, Mackenzie et al. [42] conducted a survey that found one of the primary 357 
obstacles related to integrated data repositories included data quality and standard 358 
issues. It is evident that with our improvements in clinical systems and data sharing, 359 
this issue is of great importance now more than ever. Clearer auditing methods are 360 
required to ensure high data quality is guaranteed during primary data collection and 361 
at a larger-scale for the use of clinical data in biomedical research.   362 
 363 
The scope of this literature review was limited to the small number of articles 364 
identified by the selection of keywords. It is presumed that many clinical studies 365 
undergo audits, but do not publish their methods, as they may be considered 366 
confidential by many organisations [4]. According to the ICH-GCP, the FDA does not 367 
assess the results of audits directly and rather guides the sponsor(s) on how to 368 
conduct audits [18]. However, procedures on how to audit, what to audit, the 369 
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frequency of audits, and the form and content of audits are left to the sponsor to 370 
design and determine. It is recommended that each country’s regulatory authority 371 
(European Union – European Medicines Agency (EUA), Japan – Pharmaceuticals 372 
and Medical Devices Agency (PMDA), Canada – Therapeutic Products Directorate 373 
(TPD) and Australia – Therapeutic Goods Administration (TGA)) guide this process 374 
but only seek audit reports when serious legal proceedings and/or GCP non-375 
compliance exists [18]. It is understood that the pharmaceutical industry enforces 376 
tightly regulated monitoring activities and may have determined what methods are 377 
optimal, though this again cannot be determined from the current published 378 
literature.  379 
 380 
SDV audit methods are varied because each article is assessing different primary 381 
outcomes. The majority of the literature included for the review was considered to 382 
have low levels of evidence according to study types [23]. Additionally, the focus on 383 
clinical research trials may of ruled out relevant articles from the informatics and 384 
library science literature. Limited articles took into consideration whether a SDV audit 385 
was effective in achieving quality assurance. These limitations made it difficult to 386 
determine and justify clinical significance in relation to acceptable data quality. The 387 
lack of evidence in the literature regarding methods of SDV is a strong indication of 388 
the need to conduct further research in this area. The lack of adequate detail in the 389 
original publications may also have affected the strength of our conclusions. All 390 
articles differed in their study size, country of origin, ethnicity, education level, 391 
resources and method for implementing a SDV were varied. Therefore, the main 392 
limitation of this review is being unable to compare the methods of SDV auditing 393 
against each other. As this area of research is growing, it was the researchers’ 394 
decision to not use only MeSH terms, descriptors and concepts. Consideration is 395 
required as the review spans a number of disciplines and limiting to MeSH terms 396 
may in turn limits the search strategy and number of relevant articles returned. 397 
Although MeSH terms were not incorporated in the search strategy, a stringent 398 
systematic procedure was followed and guided by the NHMRC framework and 399 
PRISMA checklist. Further, a quality-rating process was implemented to identify 400 
potential bias and a range of scientific databases were utilised as recommended by 401 




Overall analyses of included articles suggest that the importance of data structure 404 
and the added potential for correcting errors are valuable.  Future research is 405 
required focussing on the value of SDV to support trial investigators who wish to 406 
ensure data integrity, but must work within the limits of funding and resource 407 
availability. Unique and different approaches for data audit characteristics may be 408 
more appropriate and need to be taken into consideration for example; comparing 409 
RCT to observational studies. Determining an acceptable error rate is also warranted 410 
to assess the quality and monitor clinical research data. The question of “how many 411 
errors are too many?” is difficult to answer as the included variables and the 412 
robustness of the study design play a significant role in determining the amount of 413 
error.  414 
 415 
 416 
5. Conclusion 417 
This literature review provides an overview of the use of SDV auditing methods and 418 
the issues related to its use. The review demonstrates few articles reporting audit 419 
methods in a clinical setting. There is inconsistency in the methodology of SDV 420 
auditing in clinical research studies and a scarcity of evidence to support best 421 
practice. Therefore a gap in the literature has been identified and a need to assess 422 
SDV auditing methods in clinical studies. Based on the small number of identified 423 
publications and a lack of experimental evidence, no uniform SDV auditing method 424 
or approach can be determined for the conduct of clinical trials. The utilisation and 425 
improvement of SDV auditing methods are required. Based on the current literature 426 
recommendations for using a combination of a random sample of participants’ 427 
records (≥10%); both critical and non-critical variables and multiple audits (before, 428 
during and after) with quality improvement feedback should be included in the SDV 429 
audits. This combination is considered to be a cost-effective solution to ensure data 430 
quality, at least until further studies are conducted.  431 
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- Data not from a clinical trail/
research setting (n=38)
- Did not measure/report data 
quality through verifying orginal 
data with data entered to a 




Records excluded if not 
available in English language and did 
not include human participants 
(n=183)
 




- Articles on data coding, linkage 
or mining (n=12)
- Articles on other data assessment 
methods (n=12)
- Articles on electronic health 
records (n=15)
- Review articles (n=18)
- Quality of life/care studies (n=22)
- Articles on registry development and
evaluation (n=39)
- Articles on clinical trial development 
and management (=63)
-  Articles on database and technology 
infrustructute development (n=96)
- Articles on specific disease and
treatments (n=182)
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Audit 2: 39     
Current auditing process 
of the 2 databases is 
rigorous reflecting a high 
degree of accuracy 
Agreement >96% for all 
3 audits. 
Castelnuovo et 






post 4     
Introduction of an EMR 
improved data quality. 
Audit completed before 
and after introduction of 
EMR. 
Christian et al. 
(1995)27    P 
1554 
(86) N/A 11      
Audit confirmed 
adequacy of data for 
reanalysis. 
Clarke et al. 
(2008)6    C 5(25) N/A 20      
On-site SDV provided 
insight into problems 
and identified solutions 
for improvement. 
Cunningham et 
al. (2008)15    P 942(94) Annually 6     
Data quality improved 
over the study. 
Discrepancies between 
the database and 
clinical record were 
examined for accuracy. 
Duda et al. 








    
The total error was 15%. 
Re-audited records 
decreased 50% in error. 
5 out 7 sites had >10% 
error. Major errors due 
to data not entered and 
missing documents. 
Herbert et al. 
(2004)31    F 247(10) 6 months 315     
Discrepancies occurred 
in <5% of total data 
fields of the 99% of all 
audited charts 
Horbar et al. 
(1995)30    P 635(15) N/A 10      
Data keying errors 
reduced by introducing 
additional checks (logic, 
range and consistency). 
Mealer et al. 





    
99% of data values were 
successfully monitored 
by remote SDV 
compared to traditional 
SDV. 
Mphatswe et al. 




6     
Completeness and 
accuracy of data 
improved from 1st to 3rd 
audit. Accuracy was 
determined by the 
degree of agreement. 
Nahm et al. 







points 11     
Abstraction and 
transcription are most 
likely to introduce error. 
Error rates are 
dependent on the 
amount of data collected 
and the complexity of 
source documents. 
Tudur Smith et 
al (2012)33    P 533** N/A 
All key 
variables     
SDV is time-consuming, 
expensive, not 
necessarily error-free 
and identified random 
errors that had a minor 
impact. Central 
monitoring could be 
more effective than 
traditional SDV. 
Van den Broeck 





6      
Error rate <1% set as a 




data quality based on 
data flow stages. 
CRF: Case Report Form; C: Centres; EMR: Electronic Medical Record; F: Files; SDV: Source Data Verification; P: Participants. 
Data, n(%): Refers to the number (n) of participants, files or centres audited compared to the total participants, files or centres available to audit. For example, 5(25) 
is five centres included or participated in data audit from a total of 20 centres, therefore 25%.  
Key data: include critical data points to the outcome of the study. May include; but not limited to primary/secondary endpoints, adverse events, certain 
inclusion/exclusion criteria and informed consent. 
Centres: include medical and health centres/facilities and hospitals 
* Audited number (n) of participants, files or centres not available in publication. Only a percentage provided.  
** Total number of participants, files or centres not available in publication, therefore unable to calculate percentage. 
Vantongelen et 
al. (1989)34    F 
430 
(100) N/A 
All items on 
CRF     
Incorrect data transfer 
was the main source of 
error. CRF design is 
important. Knowledge 
and experience of data 
management associated 
with % error. 
Xian et al. 
(2011)32    C 147(11) N/A 35     
Accuracy of data 
elements ranged 79-
99.5%. Data elements 
with suboptimal 
accuracy should be 
targeted for 
improvement. 
Table 1: Overview of the types of trials of included articles 




Andrianopoulos et al. (2011)35 Australia Institutional Cardiac surgery 
Castelnuovo et al. (2012)14 Africa Institutional HIV/AIDS 
Christian et al. (1995)27 USA Institutional Cancer 
Clarke et al. (2008)6 USA Institutional Cardiac surgery 
Cunningham et al. (2008)15 New 
Zealand 
Institutional Cancer 
Duda et al. (2012)29 South 
America 
Institutional HIV/AIDS 
Herbert et al. (2004)31 USA Institutional Cardiac surgery 
Horbar et al. (1995)30 USA Research Low birth weight 
Mealer et al. (2013)9 USA Research Acute respiratory 
syndrome and rare 
paediatric liver disease 
Mphatswe et al. (2012)12 Africa Institutional HIV/AIDS 
Nahm et al. (2008)5 USA Institutional Drug abuse treatment 
Tudur Smith et al (2012)33 UK Research Cancer 
Van den Broeck et al (2007)28 Africa Research Micronutrient 
supplementation 
Vantongelen et al. (1989)34 Europe Research Cancer 
Xian et al. (2011)32 USA Institutional Stroke 
HIV/AIDS; Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome; UK: United 
Kingdom; USA: United States of America  
Research publication: Publications affiliated with academic research organisations 
Institutional publication: Publications affiliated with only the pharmaceutical industry 
 
